Story
AbbVie Receives FDA Approval for Parkinson's Disease Drug Juvmo
Summary
The U.S. Food and Drug Administration has approved AbbVie's Juvmo, a first-in-class selective D1/D5 receptor agonist for the treatment of Parkinson's disease. The company plans a U.S. launch for the new drug in October.
AbbVie Inc. (NYSE:ABBV) has secured approval from the U.S. Food and Drug Administration (FDA) for Juvmo (tavapadon), a new oral tablet for the treatment of Parkinson's disease. The regulatory milestone introduces a new therapeutic option for patients with the progressive neurodegenerative disorder.
A First-in-Class Therapy
The FDA's decision positions Juvmo as the first and only selective D1/D5 receptor agonist approved for this indication, according to the company. This novel mechanism of action distinguishes it from other available treatments in the competitive Parkinson's market.
The approval adds a significant asset to AbbVie's neuroscience portfolio. For investors, the successful navigation of the regulatory process and subsequent launch will be key metrics to watch as the company seeks to establish Juvmo's market share.
AdClinical Data and U.S. Launch
Regulatory clearance was granted based on positive results from the Phase 3 TEMPO program. The clinical trials demonstrated that Juvmo led to improvements in daily functioning for patients, a critical endpoint for therapies targeting chronic, debilitating conditions.
AbbVie announced its plan to make the new treatment available to patients in the United States in October. The commercial performance of Juvmo will be closely monitored as it enters the market and competes with existing therapies.
Read next
More on Stocks
Haleon Placed on Negative Catalyst Watch by J.P. Morgan on Slowing Sales
J.P. Morgan placed consumer health firm Haleon on a negative Catalyst Watch, citing weak sales momentum that threatens the company's growth targets and prompts cuts to earnings forecasts and its price target.
American Express Expands Global Acceptance to 190 Million Merchant Locations
American Express announced its cards are now accepted at over 190 million locations worldwide, with international acceptance more than doubling in four years as it works to close the gap with rivals Visa and Mastercard.
NVIDIA Shares Rise on Record $150 Billion Share Buyback Increase
The chipmaker's stock climbed in pre-market trading after it unveiled the largest-ever increase to a share repurchase program, bringing its total authorization to $235 billion.
PepsiCo Downgraded by Deutsche Bank on Doubts Over North American Recovery
Deutsche Bank cut its rating on PepsiCo to 'Hold' from 'Buy,' citing concerns that the company's turnaround efforts in its food and beverage units are yielding only temporary benefits amid a challenging consumer environment.